AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00640198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: constraint-induced language therapy (CIAT)
Description: CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
Study NCT00640198 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constraint-induced language therapy (CIAT)
Description: CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
Study NCT00640198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
Study NCT00640198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT04510025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
Study NCT03682198 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS measurements on skin, skull and dura
Description: During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
Study NCT03682198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine's effect on brain oxygenation
Description: With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
Study NCT03682198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal vs. high inspired oxygen
Description: By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
Study NCT03455777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRX
Description: Single open-label cohort
Study NCT01515722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education intervention (HEI)
Description: * \<Part 1> Understanding OAB~* \<Part 2> Behavioral/lifestyle modification~* \<Part 3> Bladder training~* \<Part 4> Understanding antimuscarinics
Study NCT03373955 — intervention group
Intervention type: DRUG
Intervention: pembrolizumab
Description: anti-programmed death 1 (PD-1) antibody
Study NCT04548297 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
Study NCT01837797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally
Study NCT01837797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 mg
Description: once daily dose, tablets, orally
Study NCT01837797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 3 mg
Description: once daily dose, tablets, orally
Study NCT04017897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
Description: Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
Study NCT00604188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone (SCH 000484)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
Study NCT00604188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone (SCH 000484)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
Study NCT00604188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex (SCH 028444)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
Study NCT04956614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immobilisation duration
Description: immobilisation duration of 2,4,6 week after suture of Achilles tendon
Study NCT01503164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Pressure Therapy (PAP)
Description: Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
Study NCT01503164 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: LifeStyle Counseling
Description: Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
Study NCT01822145 — intervention group
Intervention type: DEVICE
Intervention: ICD
Study NCT03588598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M
Description: a selective PI3Kδ inhibitor
Study NCT01804998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sentinel Node Biopsy
Description: Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
Study NCT01804998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy Assisted Gastrectomy
Description: In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: coffee, placebo enriched with polyphenols and placebo with caffeine
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee
Description: coffee, placebo enriched with polyphenols and placebo with caffeine
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee polyphenols mixed with placebo
Description: coffee polyphenols mixed with placebo
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee polyphenols mixed with placebo
Description: coffee polyphenols mixed with placebo
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin enriched with caffeine
Description: maltodextrin enriched with caffeine
Study NCT01832662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin enriched with caffeine
Description: maltodextrin enriched with caffeine
Study NCT04626986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
Study NCT04626986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast conserving surgery
Description: The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
Study NCT01227928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg daily for 24 months
Study NCT01227928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo 800 mg daily for 24 months
Study NCT01527162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFO worn
Description: Child wears their prescribed SAFO for 14 days by random assignment
Study NCT01527162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFO not worn
Description: Child does not wear their prescirbed SAFO for 14 days by random assignment
Study NCT03094455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental group
Description: Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
Study NCT03094455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
Study NCT01745276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphosfonate
Description: External pins coated by biphosfonate.
Study NCT01745276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxylapatit
Description: External pins coated by Hydroxylapatit.
Study NCT01155076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitality Product
Description: Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
Study NCT01155076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice a day for 8 weeks
Study NCT03192969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
Study NCT03192969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
Study NCT03192969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid Treatment
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Study NCT03192969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid Treatment
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Study NCT02360800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spray Fibrin Sealant
Description: Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
Study NCT02360800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Hemostasis and chest Closure Routine
Description: Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
Study NCT03269747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 2 tablets of Prednisone 20 Mg in the morning
Study NCT03269747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets in the morning
Study NCT02634814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
Study NCT02634814 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
Study NCT02634814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
Study NCT02634814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
Study NCT01475032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (BDP)
Description: Beclomethasone (BDP) for 12 weeks
Study NCT01475032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (BDP) + Formoterol Fumarate (FF)
Description: free combo Beclomethasone (BDP) + FF for 12 weeks
Study NCT02634814 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation
Description: Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day.
Study NCT02101983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside
Study NCT02101983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine Arabinoside
Study NCT03561545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weightlessness (parabolic flight)
Description: weightlessness (parabolic flight)
Study NCT04001738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct Transfer to Angio Suite
Description: Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
Study NCT01215578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: sunitinib 37.5 mg/day (per os) for 6 months
Study NCT04292639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vital Detect Pulse Oximeter
Description: The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
Study NCT01957943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SMOFLipid
Study NCT01957943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: equivalent volume of 10% glucose solution
Description: Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
Study NCT02803359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold
Study NCT04134884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
Study NCT04134884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
Study NCT01633138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy - Standard
Description: Computerized cognitive remediation therapy provided three times per week for four weeks
Study NCT01633138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy plus Contingency Management
Description: Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
Study NCT00721929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging
Study NCT02282059 — intervention group
Intervention type: DRUG
Intervention: sunitinib
Description: subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
Study NCT01657656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study NCT01340014 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension
Study NCT01340014 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
Study NCT03626311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AKBM-3031
Description: Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use.
Study NCT03626311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
Study NCT01657656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT02612350 — intervention group
Intervention type: GENETIC
Intervention: ctDNA Analysis for the Detection of Genetic Mutations
Description: Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
Study NCT04104087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Description: enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Study NCT01921114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioFlo™ Peripherally Inserted Central Catheter (PICC)